Currently, there are 70.67M common shares owned by the public and among those 53.00M shares have been available to trade.
The company’s stock has a 5-day price change of -2.53% and -3.35% over the past three months. VTYX shares are trading -6.48% year to date (YTD), with the 12-month market performance up to 4.52% higher. It has a 12-month low price of $1.67 and touched a high of $11.48 over the same period. VTYX has an average intraday trading volume of 1.41 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -9.72%, -1.15%, and -28.87% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Ventyx Biosciences Inc (NASDAQ: VTYX) shares accounts for 63.94% of the company’s 70.67M shares outstanding.
It has a market capitalization of $163.34M and a beta (3y monthly) value of 0.50. The earnings-per-share (ttm) stands at -$2.37. Price movements for the stock have been influenced by the stock’s volatility, which stands at 8.03% over the week and 11.08% over the month.
Earnings per share for the fiscal year are expected to increase by 36.44%, and 4.18% over the next financial year.
Looking at the support for the VTYX, a number of firms have released research notes about the stock. Wells Fargo stated their Overweight rating for the stock in a research note on March 12, 2024, with the firm’s price target at $7-$16. Oppenheimer coverage for the Ventyx Biosciences Inc (VTYX) stock in a research note released on March 12, 2024 offered a Outperform rating with a price target of $12. Wells Fargo was of a view on November 07, 2023 that the stock is Equal Weight, while Stifel gave the stock Hold rating on November 07, 2023, issuing a price target of $6. Oppenheimer on their part issued Perform rating on November 07, 2023.
